Research News Archives - Page 2 of 3

Research News

April 28, 2017

Charley’s Fund, Duchenne UK, and Joining Jack join forces on grant to investigate new approach to treat DMD

One of our core values is LEVERAGE. So we are very excited to join forces with partners across the Pond to fund a new research…

Laura dalle-pazze

Love0

Homepage News Research News

March 10, 2017

Promising new data about Electrical Impedance Myography for DMD

Harvard doctor and scientist Seward Rutkove recently published new data about Electrical Impedance Myography, a non-invasive outcome measure for Duchenne muscular dystrophy and other muscle diseases. Charley's…

Laura dalle-pazze

Love2

Homepage News News Research News

September 19, 2016

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys…

Charley's Fund Admin

Love1

Homepage News Research News

August 22, 2016

Summit Keeps Climbing

It's taking a long time, but it's happening! Summit Therapeutics, a UK-based company we began supporting nine years ago, is making significant progress on its experimental…

Charley's Fund Admin

Love0

Research News

June 22, 2016

Update on the HT-100 program

Earlier this week at the annual PPMD Connect Conference in Orlando, Akashi Therapeutics CMO Dr. Diana Escolar presented an update on the HT-100 program. "We…

Charley's Fund Admin

Love0

Homepage News Research News

May 22, 2016

We remain active on other medical research fronts

While we aggressively advocate for the approval of eteplirsen, we remain active on other medical research fronts. It's important to remember that eteplirsen helps 13%…

Charley's Fund Admin

Love0

Homepage News Research News

April 12, 2016

Meet the Impact Initiative

You probably already know that Charley's Fund is supporting the development of several new medicines to slow or halt Duchenne's deadly progression. Our goal is…

Charley's Fund Admin

Love0

News Research News

May 8, 2012

Patient Associations Fostering Halo’s Effect in DMD Space – BioWorld Today

By Jennifer Boggs Managing Editor For companies working in orphan diseases, support from patient advocacy groups and foundations is critical, both in terms of providing…

Charley's Fund Admin

Love0

News Research News

October 26, 2011

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia Mechelen, Belgium; 20 May 2010 – Galapagos NV (Euronext: GLPG) announced today that it…

Charley's Fund Admin

Love0

News Research News

October 15, 2007

AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy

AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy $2.45 Million Will Fund Research and Product Development Program PORTLAND,…

Charley's Fund Admin

Love0

Research News

Charley’s Fund, Duchenne UK, and Joining Jack join forces on grant to investigate new approach to treat DMD

Promising new data about Electrical Impedance Myography for DMD

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

Summit Keeps Climbing

Update on the HT-100 program

We remain active on other medical research fronts

Meet the Impact Initiative

Patient Associations Fostering Halo’s Effect in DMD Space – BioWorld Today

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia

AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy

Archives

Contact

Tax Exemption